IP Library Granted Patent US 7,772,219
Granted Patent B2
US 7,772,219 · App. 10/837,268 · Granted Aug 10, 2010

Methods of hormonal treatment utilizing extended cycle contraceptive regimens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,219
App. No.
10/837,268
Granted
Aug 10, 2010
Kind
B2
Abstract

The present invention provides extended cycle contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin. The disclosed extended cycle contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.

Claims (7)

1. A method of increasing fertility in a perimenopausal female, said method consisting essentially of administering to the female a monophasic combination of estrogen and progestin for a period of 80-90 consecutive days, in which the daily amount of estrogen is equivalent to about 10 μm to about 30 μg of ethinyl estradiol and in which the daily amount of progestin is equivalent to about 0.05 mg to about 0.20 mg of levonorgestrel, followed by a hormone-free period of 5-8 consecutive days, wherein neither estrogen nor progestin is administered to the female, and wherein hormone-free placebo is administered during said hormone-free period of 5-8 consecutive days, followed by administration of an agent to induce ovulation in the perimenopausal female.

2. The method of claim 1 , wherein the combination of estrogen and progestin is administered for at least 84 consecutive days.

3. The method of claim 1 , wherein said hormone-free placebo is administered for 7 consecutive days.

4. The method of claim 1 , wherein the agent to induce ovulation in the female is selected from the group consisting of menotropins and clomiphene citrate.

5. The method of claim 4 , wherein the daily amount of estrogen is equivalent to about 30 μg of ethinyl estradiol, and the daily amount of progestin is equivalent to about 0.15 mg of levonorgestrel.

6. The method of claim 4 , wherein said ovulation agent is a menotropin.

7. The method of claim 4 , wherein said ovulation agent is clomiphene citrate.

Assignments (3)
CHANGE OF NAME Recorded May 19, 2010
From: DURAMED PHARMACEUTICALS, INC.
To: TEVA WOMEN'S HEALTH, INC.
Reel/Frame 024402/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2005
From: BARR LABORATORIES, INC.
To: DURAMED PHARMACEUTICALS, INC.
Reel/Frame 015828/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2004
From: BEN-MAIMON, CAROLE S.; HAIT, HOWARD; REAPE, KATHLEEN Z.; BRONNENKANT, LANCE J.
To: BARR LABORATORIES, INC.
Reel/Frame 015300/0439 →